Investment Rating - The report maintains a "Buy" rating for WuXi Biologics (2269 HK) with a target price of HK$54.23, representing a potential upside of 44% from the current price of HK$37.68 [1][10][11]. Core Insights - The company is expected to see revenue and profit growth in 2025, driven by global network expansion and digital transformation initiatives. The growth trend is anticipated to continue into 2026, supported by strong research services, leading platform recognition, and an increase in drug development projects [6][10]. - The number of projects is on the rise, with a total of 945 comprehensive projects expected by 2025, including 74 clinical phase III projects. The company has reported that bispecific antibodies are the fastest-growing and most profitable molecule type, contributing nearly 20% of revenue with over 120% year-on-year growth [7][10]. - The company is enhancing its global footprint, with about half of new projects in 2025 coming from the U.S. Strategic investments are being made in U.S. facilities to bolster production capacity [8][10]. Financial Summary - Revenue projections for 2025E, 2026E, and 2027E are RMB 21,176 million, RMB 25,175 million, and RMB 29,813 million, respectively, reflecting growth rates of 13.4%, 18.9%, and 18.4% [9][15]. - The expected earnings per share (EPS) for 2025E, 2026E, and 2027E are RMB 0.87, RMB 1.03, and RMB 1.20, respectively [2][9]. - The company’s market capitalization is approximately US$5.923 billion, with a current share count of 1,228 million [1][9]. Valuation - The report employs a two-stage DCF valuation method, resulting in a target price of HK$54.23, which corresponds to a P/E ratio of 49x for 2026, slightly above the industry average of 30x [11][12]. - The report highlights a WACC of 7.9% and a perpetual growth rate adjustment to 5%, indicating a positive long-term outlook for the company [11][12].
药明生物（02269）：业绩修复与平台化能力强化推动经营表现持续提升